How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately.
Fiche publication
Date publication
juin 2023
Journal
Vaccine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie
Tous les auteurs :
Ailloud J, Branchereau M, Fall E, Juneau C, Partouche H, Bonnay S, Oudin-Doglioni D, Michel M, Gagneux-Brunon A, Bruel S, Thilly N, Gauchet A,
Lien Pubmed
Résumé
It has been proven that vaccination is effective against Human Papillomavirus (HPV) infections, genital warts, and pre-cancerous and cancerous cervical lesions. Nevertheless, the HPV vaccine coverage of 37.4 % in 2021 in France is one of the lowest in Europe. To explore and understand the reason why French population is so late compared to its neighbours, we carried out focus groups with mothers and with National Education school staff. We aimed to identify knowledge and perceptions of HPV in both study populations, as well as factors influencing HPV vaccination.
Mots clés
Decision-making, Human Papillomavirus (HPV), Vaccination, Vaccine Acceptance/Hesitancy
Référence
Vaccine. 2023 06 19;: